BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia (2023)
Brumatti, Gabriela 
; Kaloni, Deeksha ; Castro, Fabíola Attié de ; Amarante-Mendes, João Gustavo Pessini
Source: Biochemical Journal. Unidades: FCFRP, ICB
Subjects: IMUNOLOGIA, LEUCEMIA MIELOIDE AGUDA, NEOPLASIAS POR TIPO HISTOLÓGICO, PROTEÍNAS QUINASES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BRUMATTI, Gabriela et al. BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia. Biochemical Journal, v. 480, p. 161–176, 2023Tradução . . Disponível em: https://doi.org/10.1042/BCJ20210608. Acesso em: 05 nov. 2024.APA
Brumatti, G., Kaloni, D., Castro, F. A. de, & Amarante-Mendes, J. G. P. (2023). BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia. Biochemical Journal, 480, 161–176. doi:10.1042/BCJ20210608NLM
Brumatti G, Kaloni D, Castro FA de, Amarante-Mendes JGP. BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia [Internet]. Biochemical Journal. 2023 ; 480 161–176.[citado 2024 nov. 05 ] Available from: https://doi.org/10.1042/BCJ20210608Vancouver
Brumatti G, Kaloni D, Castro FA de, Amarante-Mendes JGP. BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia [Internet]. Biochemical Journal. 2023 ; 480 161–176.[citado 2024 nov. 05 ] Available from: https://doi.org/10.1042/BCJ20210608
